Fractyl Health

Historical price data

Fractyl Health's mission is to prevent, reverse, and eradicate obesity and type 2 diabetes by developing durable, organ-targeted therapies that address root causes rather than symptoms. Its key achievement is the development of the Revita DMR system, an outpatient endoscopic procedure with positive clinical data for weight maintenance post-GLP-1 therapy, now in a pivotal U.S. study (REMAIN-1). The company's strategy is built on two complementary platforms: the near-term, device-based Revita and the long-term, gene therapy-based Rejuva, aiming to shift metabolic disease treatment from chronic management to potential one-time cures.

Two organ-targeted platforms: Revita, a hydrothermal ablation device for duodenal resurfacing, and Rejuva, a locally administered AAV gene therapy for pancreatic islet reprogramming.

Fractyl differentiates from chronic GLP-1 drug makers by offering a one-time procedural solution for weight maintenance. It competes with bariatric surgery on invasiveness and with other endoscopic devices on clinical experience and IP. Its gene therapy platform is a first-mover in a nascent field.